Ozempic Maker Novo Nordisk Is Plunging 20%. Time To Sell Or Buy More?
Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) watched its stock plummet 20% after slashing its full-year sales and profit outlook for the second time this year. The announcement, ahead of the full Q2 2025 results due Aug. 6, reported 18% sales growth and 29% operating profit… Read More »Ozempic Maker Novo Nordisk Is Plunging 20%. Time To Sell Or Buy More?